Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data Journal Article


Authors: Grigoriadis, A.; Mackay, A.; Reis-Filho, J. S.; Steele, D.; Iseli, C.; Stevenson, B. J.; Jongeneel, C. V.; Valgeirsson, H.; Fenwick, K.; Iravani, M.; Leao, M.; Simpson, A. J. G.; Strausberg, R. L.; Jat, P. S.; Ashworth, A.; Neville, A. M.; O'Hare, M. J.
Article Title: Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data
Abstract: Introduction: Diverse microarray and sequencing technologies have been widely used to characterise the molecular changes in malignant epithelial cells in breast cancers. Such gene expression studies to identify markers and targets in tumour cells are, however, compromised by the cellular heterogeneity of solid breast tumours and by the lack of appropriate counterparts representing normal breast epithelial cells. Methods: Malignant neoplastic epithelial cells from primary breast cancers and luminal and myoepithelial cells isolated from normal human breast tissue were isolated by immunomagnetic separation methods. Pools of RNA from highly enriched preparations of these cell types were subjected to expression profiling using massively parallel signature sequencing (MPSS) and four different genome wide microarray platforms. Functional related transcripts of the differential tumour epithelial transcriptome were used for gene set enrichment analysis to identify enrichment of luminal and myoepithelial type genes. Clinical pathological validation of a small number of genes was performed on tissue microarrays. Results: MPSS identified 6,553 differentially expressed genes between the pool of normal luminal cells and that of primary tumours substantially enriched for epithelial cells, of which 98% were represented and 60% were confirmed by microarray profiling. Significant expression level changes between these two samples detected only by microarray technology were shown by 4,149 transcripts, resulting in a combined differential tumour epithelial transcriptome of 8,051 genes. Microarray gene signatures identified a comprehensive list of 907 and 955 transcripts whose expression differed between luminal epithelial cells and myoepithelial cells, respectively. Functional annotation and gene set enrichment analysis highlighted a group of genes related to skeletal development that were associated with the myoepithelial/basal cells and upregulated in the tumour sample. One of the most highly overexpressed genes in this category, that encoding periostin, was analysed immunohistochemically on breast cancer tissue microarrays and its expression in neoplastic cells correlated with poor outcome in a cohort of poor prognosis estrogen receptor-positive tumours. Conclusion: Using highly enriched cell populations in combination with multiplatform gene expression profiling studies, a comprehensive analysis of molecular changes between the normal and malignant breast tissue was established. This study provides a basis for the identification of novel and potentially important targets for diagnosis, prognosis and therapy in breast cancer. © 2006 Grigoriadis et al.; licensee BioMed Central Ltd.
Keywords: immunohistochemistry; controlled study; unclassified drug; human cell; sequence analysis; treatment planning; molecular genetics; gene targeting; gene overexpression; gene expression profiling; interleukin 10; interleukin 1beta; interleukin 8; validation study; cell population; cell specificity; scleroprotein; rna; gene expression regulation; basal cell; diagnostic value; nucleotide sequence; cancer infiltration; breast carcinoma; cell isolation; kallikrein; interleukin 6; transforming growth factor beta1; epithelium cell; myoepithelium cell; upregulation; dna microarray; tissue microarray; cytokeratin 14; estrogen receptor; interleukin 1alpha; unindexed sequence; transcriptome; intraductal carcinoma; glycoprotein; keratinocyte growth factor; fibroblast growth factor; marker gene; complementary dna; transforming growth factor beta3; gene technology; cytokeratin 10; rab protein; fibroblast growth factor 13; fibroblast growth factor 4; nerve growth factor beta subunit; periostin; ral protein; rap protein; massively parallel signature sequencing
Journal Title: Breast Cancer Research
Volume: 8
Issue: 5
ISSN: 1465-5411
Publisher: Biomed Central Ltd  
Date Published: 2006-10-02
Start Page: R56
Language: English
DOI: 10.1186/bcr1604
PROVIDER: scopus
PMCID: PMC1779497
PUBMED: 17014703
DOI/URL:
Notes: --- - "Cited By (since 1996): 60" - "Export Date: 4 June 2012" - "CODEN: BCRRC" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew John Simpson
    31 Simpson